RecruitingNot ApplicableNCT06235112

AI Detection of Incidental Coronary Artery Calcium to Enhance Cardiovascular Disease Prevention

AI Detection of Incidental Coronary Artery Calcium to Enhance Cardiovascular Disease Prevention: A Multicenter Randomized Trial


Sponsor

Brigham and Women's Hospital

Enrollment

1,500 participants

Start Date

Jul 31, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

AI INFORM is a multicenter randomized trial that will test the hypothesis that providing clinicians information on the presence and amount of coronary artery calcifications (CAC), will result in initiation or intensification of preventive therapies. The study will use a cloud-based artificial intelligence (AI) platform (Nanox.AI) that can analyze non contrast chest CT and estimate the amount of CAC.


Eligibility

Min Age: 40 YearsMax Age: 75 Years

Inclusion Criteria1

  • Patients aged between 40-75 with prior chest CT within last 3 years

Exclusion Criteria3

  • Prior coronary artery disease
  • Prior cancer
  • Other life-limiting condition

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEElectronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment

The intervention involves electronic health record, email, or letter notification about the presence of coronary artery calcification on chest CT and recommendation of preventive therapy. This is based on results of the automatic detection of coronary artery calcification from AI device (software).


Locations(1)

Brigham and Women's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06235112


Related Trials